import dtpImg from '../assets/article-dtp.png'
import glp1Img from '../assets/article-glp1.png'
import empImg from '../assets/article-empiricism.png'

export const ARTICLES = [
  {
    slug: 'direct-to-patient',
    tag: 'Direct-to-Patient',
    title: 'Direct-to-Patient Pharma Models: A Strategic and Regulatory Appraisal of Risks, Opportunities, and the Critical Role of Medical Affairs',
    author: 'Dillon Shokar',
    date: 'Oct 3, 2025',
    readTime: '8 min read',
    bg: '#254733',
    content: [
      {
        type: 'abstract',
        text: 'Direct-to-patient (DTP) pharmaceutical distribution models, which integrate telehealth consultations, digital prescribing, and direct medication delivery, are rapidly expanding in the United States. High-profile initiatives such as Eli Lilly\'s LillyDirect, Pfizer\'s emerging digital channels, and consumer brands like Hims & Hers highlight both the disruptive potential and the regulatory fragility of this approach. While these models promise improved access, adherence, and patient convenience, they raise significant concerns around affordability, care fragmentation, medicalization, and regulatory compliance. Using a PESTLE framework (Political, Economic, Social, Technological, Legal, Ethical), I critically appraise DTP distribution models through academic literature, policy guidance, and case examples. I also distinguish them from direct-to-consumer (DTC) advertising, which faces intensifying regulatory curtailment and political attack. My central argument is that DTP distribution models can only be sustainable if governed by Medical Affairs, which provides the necessary guardrails of scientific integrity, evidence generation, and patient trust. For pharmaceutical executives, the strategic imperative is clear: assess DTP readiness systematically, invest in Medical Affairs-led governance, and design evidence-driven pilot programs. Without these foundations, DTP risks not only commercial underperformance but also reputational and regulatory failure.',
      },
      { type: 'h2', text: 'Introduction' },
      { type: 'p', text: 'The pharmaceutical industry is undergoing a structural shift in how patients access medicines. Historically dependent on physician visits, retail pharmacies, and PBM-driven formularies, the pathway from prescription to treatment is increasingly mediated by digital channels. In January 2024, Eli Lilly launched LillyDirect, a direct-to-patient (DTP) distribution model offering telehealth consultations and integrated pharmacy fulfillment for obesity drugs (Rome, 2024). Pfizer has also piloted consumer-facing digital channels for chronic therapies (Biopharma Dive, 2024). In parallel, consumer health brands such as Hims & Hers and Ro have scaled comparable distribution models across sexual health, dermatology, and mental health (Ventola, 2011; Fain, 2014).' },
      { type: 'p', text: 'It is essential, however, to distinguish DTP distribution models from direct-to-consumer (DTC) advertising. The former is rising, driven by telemedicine adoption, digital pharmacies, and patient demand for convenience. The latter is under mounting scrutiny. The FDA has begun classifying telehealth and influencer-driven promotion as DTC advertising, subjecting them to the same risk-disclosure requirements as television or print campaigns (FDA, 2025; HHS, 2025). Political voices such as Robert Kennedy Jr. have sharpened the critique, framing DTC advertising of GLP-1s and psychiatric drugs as emblematic of over-medicalization (Pew Research, 2023).' },
      { type: 'p', text: 'My argument is that DTP distribution models cannot be insulated from this regulatory climate. Their promotional aspects blur into advertising, and without governance by Medical Affairs, the very features that make DTP attractive, such as convenience, direct engagement, and patient empowerment, may become liabilities. I therefore use a PESTLE framework to appraise the risks and opportunities of DTP distribution models and argue that Medical Affairs must lead their design, oversight, and evidence generation.' },

      { type: 'h2', text: 'Analytical Framework: A PESTLE Appraisal of DTP Distribution Models' },
      { type: 'labeled', label: 'Political', text: 'DTP distribution models operate in a volatile political environment. Both Republican and Democratic administrations have prioritized lowering prescription drug costs (Kesselheim et al., 2022). Populist critiques of "Big Pharma" have amplified narratives around over-medicalization, especially in obesity and mental health (Pew Research, 2023). I view this as creating a reputational tightrope: policymakers see direct engagement with patients by manufacturers as potentially inflationary rather than cost-saving. Any perception that DTP bypasses PBMs or erodes rebates risks triggering further legislative scrutiny.' },
      { type: 'labeled', label: 'Economic', text: 'Evidence suggests DTP distribution does not uniformly lower patient costs. Anderson et al. (2024) found only 9 of 33 generics (27 percent) offered through a DTP pharmacy were cheaper at the patient level compared to commercial insurance, though 29 (88 percent) were cheaper in terms of total system cost. This bifurcation complicates payer alignment: aggregate efficiency gains do not always translate into individual affordability. Moreover, rebate structures mean bypassing PBMs risks raising premiums. Manufacturers may capture short-term margin through refill capture and abandonment reduction (IQVIA, 2023), but the sustainability of those economics depends on payer acceptance, which will be influenced by how closely distribution models are perceived to resemble curtailed DTC advertising.' },
      { type: 'labeled', label: 'Social', text: 'DTP distribution models are most visible in therapy areas where stigma and access barriers are high, such as obesity, sexual health, dermatology, and mental health (Patel et al., 2021). Evidence suggests telemedicine improves initiation and continuity of care in these domains (Goldstein et al., 2022). Yet patient trust in pharma remains fragile, with fewer than 40 percent of Americans expressing confidence in pharmaceutical companies (Edelman, 2024). If DTP distribution is seen as advertising in disguise, it risks reinforcing distrust rather than reducing stigma.' },
      { type: 'labeled', label: 'Technological', text: 'The technological backbone of DTP distribution includes telehealth platforms, automated benefit verification, and integrated logistics (Greenhalgh et al., 2018). These same tools, however, are often embedded in marketing interfaces such as websites with patient journeys, apps with push notifications, or chatbots that double as product selectors. As regulators increasingly treat these as promotional, the technological overlap between distribution and advertising exposes companies to compliance risks unless Medical Affairs sets the boundaries.' },
      { type: 'labeled', label: 'Legal', text: 'The FDA\'s 2025 warning to Hims & Hers for misbranding compounded semaglutide illustrates the legal fragility of models that conflate distribution with promotion (FDA, 2025). The company\'s high-profile Super Bowl ad, criticized for omitting risk disclosures (Reuters, 2025), blurred the line between DTP distribution and DTC advertising. More broadly, HHS now requires digital, telehealth, and influencer-based touchpoints to be treated as advertising (HHS, 2025). Legally, this means every patient-facing asset in a DTP distribution model can be classified as promotional labeling unless governed with rigorous oversight.' },
      { type: 'labeled', label: 'Ethical', text: 'The ethical critique of DTP distribution is inseparable from the critique of DTC advertising. Both risk incentivizing demand for drugs beyond clinically appropriate populations. Kennedy Jr. and others argue that pharma channels fuel over-medicalization (Pew Research, 2023). At the same time, telehealth distribution can expand access for underserved groups, particularly in rural areas (Patel et al., 2021). I believe that the ethical sustainability of DTP hinges on Medical Affairs-led stewardship, which defines eligibility, embeds deprescribing pathways, and ensures that distribution expands appropriate access without amplifying unnecessary consumption.' },

      { type: 'h2', text: 'Case Studies and Evidence Review' },
      { type: 'p', text: 'LillyDirect represents the archetype of a DTP distribution model with manufacturer ownership. Early reports suggest uptake has been significant in obesity treatment, but payer acceptance remains uncertain (Rome, 2024). By contrast, Amazon\'s PillPack and Mark Cuban\'s Cost Plus Drugs demonstrate that technology-driven pharmacy models can deliver system-level cost savings, but their integration with manufacturers is limited (IQVIA, 2023).' },
      { type: 'p', text: 'The clearest warning comes from Hims & Hers. While its DTP distribution has scaled rapidly in sexual health and weight loss, its reliance on consumer advertising has triggered regulatory sanction. In 2025, the FDA issued a misbranding warning for its compounded GLP-1 products (FDA, 2025), and its Super Bowl ad was censured for lack of balanced risk communication (Reuters, 2025). This illustrates the strategic danger: when DTP distribution overlaps too closely with DTC advertising, the model becomes politically and legally vulnerable.' },

      { type: 'h2', text: 'Why Medical Affairs Must Lead' },
      { type: 'p', text: 'Recent regulatory developments underscore that every digital patient-facing interaction may be classified as advertising. In 2025, the FDA issued guidance equating digital, influencer, and telehealth promotion with traditional DTC channels (HHS, 2025; Latham & Watkins, 2025). In practice, this means that distribution platforms, even when primarily transactional, fall within the remit of promotional regulation. Marketing teams cannot alone shoulder this burden. Only Medical Affairs has the mandate and credibility to ensure that DTP distribution becomes a channel for evidence-based care rather than an extension of advertising.' },
      { type: 'p', text: 'In my view, Medical Affairs must lead in three domains. First, governance: ownership of patient-facing content, AE monitoring, and escalation pathways. Second, evidence: real-world evidence generation that links DTP with adherence, outcomes, and cost offsets, capable of satisfying both payers and regulators. Third, stewardship: integration of DTP with the broader continuum of care, including data flows to primary care and deprescribing frameworks in high-risk areas such as GLP-1s.' },

      { type: 'h2', text: 'Strategic Implications for Pharma' },
      { type: 'p', text: 'The implications are clear. DTP distribution models are strategically viable only when Medical Affairs leads governance. For executives, I recommend three immediate steps. First, conduct a DTP readiness audit, mapping therapy areas against patient need, payer acceptance, and regulatory risk. Second, establish a Medical Affairs governance board with veto rights over digital touchpoints, chatbot scripts, and promotional assets. Third, launch pilot programs tied to formal RWE studies, publishing outcomes to demonstrate stewardship and transparency. These steps not only safeguard compliance but also build trust with payers, regulators, and patients.' },

      { type: 'h2', text: 'The Human Dimension' },
      { type: 'p', text: 'Patients are not abstractions in a distribution channel. They are individuals navigating illness, stigma, and uncertainty. A woman considering a GLP-1 is weighing affordability, social judgment, and health risks. A man using a digital app for migraine therapy seeks relief without an ER visit, not an algorithmic sales journey. If DTP distribution models are reduced to transaction channels, they will fail. If they are governed by Medical Affairs with patient trust at the center, they can succeed.' },

      { type: 'h2', text: 'Final Thoughts' },
      { type: 'p', text: 'DTP distribution models are rising, while DTC advertising is facing regulatory curtailment and political attack. The overlap between the two creates strategic risk, since distribution platforms rely on promotional infrastructures that are under scrutiny. My conclusion is unambiguous: without Medical Affairs leadership, DTP distribution will not be sustainable. With Medical Affairs leadership, however, these models can become credible patient-first capabilities that improve access, demonstrate outcomes, and create value for all stakeholders.' },
      { type: 'p', text: 'For executives considering whether to launch or scale DTP distribution, the next step must be a structured strategic assessment. At Princeton Biopartners, my colleagues and I have advised Fortune 500 pharma and emerging biotech firms on Medical Affairs strategy, payer engagement, and evidence generation. If your organisation is evaluating DTP distribution, I invite you to connect with me to design an evidence-based roadmap that ensures your model is compliant, sustainable, and trusted.' },

      { type: 'image', src: dtpImg, caption: 'Figure: Cost reduction in direct-to-consumer pharmacy vs commercial insurance for generics (Anderson et al., 2024).' },

      {
        type: 'sources',
        items: [
          'Anderson, T.S., Good, C.B., Hernandez, I., Kesselheim, A.S., & Rome, B.N. (2024). Comparison of Out-of-Pocket and Total Costs for Generic Medications Dispensed by a Direct-to-Consumer Pharmacy vs Commercial Insurers. JAMA Network Open, 7(5), e2412608.',
          'Biopharma Dive. (2024). Pfizer, Eli Lilly bet on direct-to-consumer GLP-1 channels.',
          'Bollmeier, S.G., Kesselheim, A.S., & Fain, K.M. (2023). Prescription advertising in the digital age: patient safety implications. Journal of Law, Medicine & Ethics, 51(3), 412–419.',
          'Edelman. (2024). Edelman Trust Barometer: Healthcare.',
          'Fain, K.M. (2014). Mind the Gap: Understanding the Effects of Pharmaceutical Direct-to-Consumer Advertising. Pharmacoepidemiology and Drug Safety, 23(3), 235–241.',
          'FDA. (2025). Warning Letter to Hims & Hers Health, Inc. Silver Spring, MD.',
          'Goldstein, C.M. et al. (2022). Telemedicine prescribing and medication adherence. JAMA Internal Medicine, 182(6), 540–548.',
          'Greenhalgh, T., Wherton, J., Shaw, S., & Morrison, C. (2018). Video consultations for healthcare: evidence review. BMJ, 361, k436.',
          'HHS. (2025). FDA and HHS Announce New Standards for Transparency in Digital Drug Advertising. Washington, DC.',
          'IQVIA Institute. (2023). The Use of Medicines in the U.S.: Patterns and Insights.',
          'Kesselheim, A.S., Avorn, J., & Sarpatwari, A. (2022). The high cost of prescription drugs in the US: causes and solutions. BMJ, 372, n570.',
          'Latham & Watkins LLP. (2025). FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising. Client Alert, September 2025.',
          'Patel, S.Y. et al. (2021). Trends in outpatient telemedicine use during the COVID-19 pandemic. Annals of Internal Medicine, 174(1), 92–95.',
          'Pew Research Center. (2023). Public opinion on pharmaceutical companies and healthcare affordability.',
          'Reuters. (2025). FDA chief says Hims & Hers Super Bowl ad violated drug promotion rules. Reuters Health News, September 2025.',
          'Rome, B.N. (2024). Direct-to-Consumer Drug Company Pharmacies. JAMA, 331(2), 123–124.',
          'Ventola, C.L. (2011). Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? Pharmacy and Therapeutics, 36(10), 669–684.',
        ],
      },
    ],
  },

  {
    slug: 'glp1-longevity',
    tag: 'AI & Longevity',
    title: 'GLP‑1, SGLT2 and AI in Longevity: Where the Real Value Lies',
    author: 'Dillon Shokar',
    date: 'Jun 8, 2025',
    readTime: '4 min read',
    bg: '#1C3A28',
    content: [
      { type: 'h2', text: 'Background: Biology Meets Commercial Reality' },
      { type: 'p', text: 'Santulli et al. (2024) present a compelling scientific hypothesis: that GLP‑1 receptor agonists and SGLT2 inhibitors, originally developed for type 2 diabetes, may exert systemic effects relevant to human longevity. These include reductions in cardiovascular and renal risk, anti-inflammatory properties, and potential neuroprotective effects. Concurrently, artificial intelligence is transforming how we quantify biological age, stratify populations, and model intervention impact. Tools such as epigenetic clocks and digital biomarkers (Horvath and Raj, 2018; Zhavoronkov et al., 2019) are increasingly used in early-phase development and observational studies.' },
      { type: 'p', text: 'The convergence of drug repurposing and computational biomarkers appears to represent a promising direction for translational geroscience. However, for investors and pharmaceutical decision-makers, the pertinent question is not whether these ideas are interesting, but whether they are investable.' },

      { type: 'h2', text: 'Context: What Is Viable, Reimbursable, and Strategically Defensible' },

      { type: 'h3', text: 'Aging is not a regulatory indication' },
      { type: 'p', text: 'Despite scientific progress, neither the FDA nor EMA currently recognise "ageing" or "healthspan extension" as formal clinical indications. Ageing remains a risk factor rather than a disease. Trials such as TAME (metformin) have helped build momentum, but without a validated surrogate endpoint or reimbursed clinical condition, the commercial pathway remains undefined.' },

      { type: 'h3', text: 'SGLT2 inhibitors are approaching loss of exclusivity. There is no viable business case for longevity.' },
      { type: 'p', text: 'SGLT2 inhibitors, such as dapagliflozin and empagliflozin, are nearing generic entry in key markets. In the US, exclusivity expires by 2025 or 2026, and many patents in Europe are already weak or expired. Pursuing a longevity indication on these compounds would entail considerable clinical development cost, without the benefit of exclusivity, premium pricing, or payer traction. From an investment perspective, this offers poor return on capital.' },

      { type: 'h3', text: 'GLP‑1 receptor agonists are more promising, but require precision' },
      { type: 'p', text: 'By contrast, GLP‑1 analogues, such as semaglutide and tirzepatide, retain patent protection well into the next decade. These assets are actively expanding into obesity, cardiovascular prevention, NASH, and potentially age-related muscle or cognitive decline. In this context, AI biomarkers could help refine population targeting or dose optimisation. However, the focus must remain on reimbursable endpoints, not speculative "longevity" claims.' },

      { type: 'h3', text: 'AI biomarkers have potential, but should not be overstated' },
      { type: 'p', text: 'AI-generated ageing clocks and biological signatures are a useful innovation in the toolkit of R&D efficiency. They can support responder identification, adaptive trial design, and long-term risk modelling. However:' },
      { type: 'ul', items: [
        'No AI biomarker is currently accepted as a surrogate endpoint by regulators.',
        'Most are trained on publicly available data, limiting intellectual property defensibility.',
        'Their biological mechanisms are often unclear, which reduces their regulatory credibility.',
      ]},
      { type: 'p', text: 'In short, AI biomarkers may streamline development. However, they are unlikely to unlock reimbursement or regulatory approval on their own.' },

      { type: 'h2', text: 'Implications: What Should Actually Guide Investment and Development' },
      { type: 'p', text: 'A credible longevity strategy must be built on three foundations: exclusivity, clinical relevance, and regulatory feasibility. Five principles apply.' },

      { type: 'h3', text: '1. Focus on reimbursable, age-related indications' },
      { type: 'p', text: 'Investors and developers should prioritise conditions where biological ageing plays a known role, such as frailty, sarcopenia, cognitive impairment in metabolic disease, or CKD-related muscle loss. These offer viable trial endpoints, payer engagement pathways, and regulatory precedents.' },

      { type: 'h3', text: '2. Do not pursue ageing claims on compounds nearing patent expiry' },
      { type: 'p', text: 'SGLT2 inhibitors, while mechanistically interesting, offer no remaining exclusivity. There is no justification for launching a clinical programme in this area unless paired with a differentiated formulation, delivery device, or diagnostic layer that restores commercial defensibility.' },

      { type: 'h3', text: '3. GLP‑1s provide a viable commercial bridge, but require positioning discipline' },
      { type: 'p', text: 'The GLP‑1 class offers scope for lifecycle extension and indication stacking. However, any expansion into age-adjacent use cases must be underpinned by reimbursable endpoints and robust clinical design. "Healthspan" as a label is unworkable. Function, independence, or cardiovascular protection may be more defensible framings.' },

      { type: 'h3', text: '4. Treat AI biomarkers as operational tools, not endpoints' },
      { type: 'p', text: 'AI biomarkers should be embedded in development workflows to enhance trial efficiency. They are most valuable when supported by proprietary datasets, feedback loops, and early-stage regulatory dialogue. Mere model accuracy is insufficient. Regulators require clarity, reproducibility, and proven clinical relevance.' },

      { type: 'h3', text: '5. Prioritise companies that operate at the interface of biology, regulation, and data' },
      { type: 'p', text: 'The most investable platforms will combine:' },
      { type: 'ul', items: [
        'A validated biological mechanism',
        'Exclusive access to trial-grade datasets',
        'Biomarkers that inform development or payer strategy',
        'Ongoing engagement with regulators',
      ]},
      { type: 'p', text: 'These firms are more likely to secure co-development partnerships, command premium valuations, and deliver strong, risk-adjusted returns.' },

      { type: 'h2', text: 'Final Thought' },
      { type: 'p', text: 'Santulli et al. (2024) describe a scientifically rich and emerging area of exploration. Yet in the commercial world, strategy must go beyond enthusiasm. The next wave of value in longevity will be captured not by those who make the boldest claims, but by those who align biology, regulatory reality, and market structure with discipline and precision.' },
      { type: 'p', text: 'In short, investors should look not for "anti-ageing" stories, but for commercially coherent, age-relevant strategies that deliver exclusivity, reimbursement, and a measurable return on investment.' },

      { type: 'image', src: glp1Img, caption: '' },

      { type: 'credential', text: 'Dillon Shokar, (Biostatistics, King\'s College London; Data Science, Harvard), CFA · Biopharma Venture Partner | Strategy Consultant' },

      {
        type: 'sources',
        items: [
          'Fuellen, G., Liesenfeld, D., Kowald, A., et al., 2019. Health and aging: unifying concepts, scores, biomarkers and pathways. Aging Disease, 10(4), pp.883–900.',
          'Horvath, S. and Raj, K., 2018. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 19(6), pp.371–384.',
          'Santulli, G., Mone, P., Varzideh, F., et al., 2024. GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools? Future Cardiology, 21(1), pp.5–8.',
          'Zhavoronkov, A., Mamoshina, P., Vanhaelen, Q., et al., 2019. Artificial intelligence for aging and longevity research: recent advances and perspectives. Ageing Research Reviews, 49, pp.49–66.',
        ],
      },
    ],
  },

  {
    slug: 'end-of-empiricism',
    tag: 'Precision Medicine',
    title: 'The End of Empiricism: Merck Bets Big on Biomarker-Led Oncology',
    author: 'Dillon Shokar',
    date: 'May 13, 2025',
    readTime: '5 min read',
    bg: '#2E5040',
    content: [
      { type: 'h2', text: 'Background: ASCO 2025 and the Normalization of Precision' },
      { type: 'p', text: 'At ASCO 2025, precision medicine no longer presented as an aspirational ideal. It has become a practical necessity. Across tumor types and modalities, the most prominent development programs were those guided by biomarker-driven patient selection. Biomarkers have become central to clinical trial design, regulatory alignment, and commercial differentiation. Their role is expanding from predictive diagnostics into tools for adaptive trial refinement, real-world patient stratification, and even drug lifecycle extension.' },
      { type: 'p', text: 'The strategic rationale is clear.' },
      { type: 'ul', items: [
        'From a regulatory standpoint, biomarker-based enrichment supports accelerated approvals and stronger label claims.',
        'From a clinical development standpoint, it enables higher responder rates and greater trial efficiency.',
        'From a commercial standpoint, it underpins value-based pricing by linking therapy to measurable clinical benefit in defined subpopulations.',
      ]},
      { type: 'p', text: 'These signals point to a structural shift. Successful oncology pipelines are increasingly organized not by modality but by the strength of their biomarker-linked development logic.' },

      { type: 'h2', text: "Context: Merck's Reorientation Around Precision Oncology" },
      { type: 'p', text: "Merck's June 2nd 2025 investor call, held alongside ASCO, illustrates a deliberate and systematic reorientation of its oncology strategy around precision medicine. Several developments stand out." },

      { type: 'h3', text: 'Expanding Beyond PD-L1: Toward Multi-Modal Biomarker Strategies' },
      { type: 'p', text: "While Merck continues to advance KEYTRUDA's PD-L1-driven indications, including new formulations such as subcutaneous delivery for improved accessibility, the company is also clearly broadening its biomarker footprint. Across discovery and development, Merck is investing in digital pathology, multiplexed immunohistochemistry, and AI-supported imaging biomarkers. These tools are being applied particularly in bladder, gynecologic, and hematologic cancers, where standard biomarker frameworks remain underdeveloped." },
      { type: 'p', text: 'This evolution reflects a broader industry trend toward more integrated, multi-modal biomarker strategies. Rather than relying solely on single-protein expression, companies are increasingly incorporating composite biomarkers and digitally enriched endpoints to improve predictive power and refine patient selection.' },
      { type: 'p', text: "However, this shift also highlights the limitations of first-generation biomarkers like PD-L1. Assay variability, dynamic expression across tumor microenvironments, and weak correlation with long-term benefit continue to challenge reproducibility. Similarly, in modalities like antibody-drug conjugates (ADCs), target expression alone does not guarantee efficacy. Payload potency, linker stability, and intratumoral heterogeneity frequently shape therapeutic response more than antigen presence itself." },
      { type: 'p', text: "Merck's strategy suggests a recognition of these complexities. By expanding its biomarker infrastructure across AI, pathology, and in silico modeling, the company is positioning itself to navigate the next chapter of precision oncology—one that depends less on static markers and more on dynamic, context-aware signatures." },

      { type: 'h3', text: 'Portfolio Prioritization Through Precision' },
      { type: 'p', text: "Merck executives emphasized that portfolio prioritization is increasingly being driven by biomarker viability. The company is focusing on indications where stratification is feasible, scalable, and clinically meaningful. For instance, it is allocating resources toward solid tumors in women's health, which account for approximately 30 percent of anticipated pipeline revenue by the mid-2030s, and hematologic malignancies, which contribute approximately 15 percent." },
      { type: 'p', text: 'These areas offer clear opportunities for biomarker-defined subgroups to enhance both clinical outcomes and payer alignment. For example, in endometrial cancer, mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) status guide the use of immune checkpoint inhibitors such as pembrolizumab. In triple-negative breast cancer, PD-L1 expression and BRCA mutation status inform the use of immunotherapy and PARP inhibitors. In hematologic malignancies like diffuse large B-cell lymphoma (DLBCL), CD19 expression determines eligibility for CAR-T therapies, while molecular profiling helps distinguish high-risk subtypes that may require tailored interventions.' },
      { type: 'p', text: "Even so, resistance mechanisms, tumor evolution, and changes in biomarker expression over time can erode the durability of these strategies. As Merck deepens its investment in precision platforms, these biological realities must inform both trial design and post-marketing surveillance." },

      { type: 'h3', text: 'Embedding AI and Computational Trial Design' },
      { type: 'p', text: 'In addition to classical biomarker stratification, Merck is applying AI to pre-trial modeling. By simulating likely responders based on multi-omic and imaging data, the company reduces uncertainty, particularly in early-phase trials. This aligns with a broader trend toward in silico patient profiling as a complement to real-world evidence.' },
      { type: 'p', text: "Yet Merck is not alone in this space. Roche, AstraZeneca, and several biotechs are also pursuing trial optimization through predictive modeling. The question for investors is whether Merck's data, infrastructure, or clinical network give it a sustained executional edge. Without clearer articulation of what is proprietary versus commoditized, competitive differentiation remains ambiguous." },

      { type: 'h2', text: 'Implications: Strategic Consequences for the Biopharma Ecosystem' },
      { type: 'p', text: "Merck's approach offers a set of implications for both incumbents and emerging biotech companies." },

      { type: 'h3', text: 'Clinical Development Will Become Smaller, Smarter, and More Selective' },
      { type: 'p', text: 'The assumption that large, empiric Phase III trials remain the gold standard is giving way to leaner, biomarker-enriched studies with stronger signal-to-noise ratios. For companies that can execute this model, time-to-decision shortens and the cost of failure declines. However, the risk-adjusted cost of biomarker validation, companion diagnostic development, and regulatory harmonization remains high.' },

      { type: 'h3', text: 'Companion Diagnostics and Formulation Innovation Will Anchor Competitive Advantage' },
      { type: 'p', text: "Merck's subcutaneous KEYTRUDA program is not simply a delivery optimization. It is part of a broader strategy to enhance access, adherence, and ultimately outcomes in biomarker-defined populations. Companion diagnostics and patient-centric formulations are now strategic assets. Nevertheless, payer resistance to reimbursing diagnostics and new formulations can slow uptake. Regulatory frameworks for co-approval also add complexity." },

      { type: 'h3', text: 'Data Integration Will Define Differentiation' },
      { type: 'p', text: "As biomarkers become more complex, ranging from spatial transcriptomics to AI-derived radiomic signatures, the ability to integrate clinical, digital, and molecular datasets will define future leaders. Merck's investment in digital pathology and AI-driven stratification positions it well. Yet execution will depend on cross-functional capabilities that are still being built across the industry." },

      { type: 'h3', text: 'Capital Markets Will Reward Clarity of Biomarker Strategy' },
      { type: 'p', text: 'From a financing perspective, companies with clearly defined biomarker strategies and demonstrated success in executing stratified trials will attract higher valuations, stronger business development interest, and faster regulatory alignment. Precision is no longer a scientific differentiator. It is a signaling mechanism to capital markets that the underlying asset is clinically de-risked and commercially viable. Still, the cost of being wrong, backing a biomarker hypothesis that fails in Phase III, remains substantial.' },

      { type: 'h2', text: 'Conclusion' },
      { type: 'p', text: "Merck's current oncology strategy exemplifies a broader shift in biopharmaceutical R&D. The industry is moving from population-based empiricism to biologically informed precision. Biomarker-driven development is not a temporary trend. It represents a structural reconfiguration of how therapies are discovered, validated, and delivered." },
      { type: 'p', text: "However, precision medicine introduces its own risks. Assay reproducibility, biological variability, and resistance dynamics demand a more adaptive and humble model of drug development. Merck's long-term success will depend not only on its ability to integrate biomarkers across the pipeline but also on its ability to respond when those biomarkers inevitably fall short." },
      { type: 'p', text: 'For investors, developers, and policymakers alike, the message is clear. The value chain now begins at the biomarker, but it does not end there.' },

      { type: 'image', src: empImg, caption: 'Source: Merck Investors' },

      { type: 'credential', text: 'Dillon Shokar, (Biostatistics, King\'s College London; Data Science, Harvard), CFA · Biopharma Venture Partner | Strategy Consultant' },

      {
        type: 'sources',
        items: [
          'Merck & Co. (2025). Investor Call Transcript, June 2, 2025.',
        ],
      },
    ],
  },
]

export function getArticle(slug) {
  return ARTICLES.find(a => a.slug === slug)
}
